Safety and Efficacy of Mosunetuzumab: Experience in the Hospital Cardinale Giovanni Panico.

BACKGROUND/

OBJECTIVE

Follicular lymphoma (FL) is one of the most common indolent B-cell non-Hodgkin lymphomas (NHL) and is characterized by recurrent relapses despite advances in therapy. Bispecific antibodies that redirect T lymphocytes toward malignant B cells represent a major innovation in the treatment of relapsed or refractory disease. Mosunetuzumab is a CD20×CD3 bispecific antibody that induces T-cell mediated cytotoxicity against B-cell malignancies. In this manuscript, we describe the clinical experience with mosunetuzumab in three patients with relapsed or refractory FL treated at the Hospital Card. G. Panico, Tricase (LE).

METHODS

Clinical history, prior therapies, treatment responses, and safety outcomes are reported.

RESULTS

The cases illustrate the potential efficacy and manageable safety profile of mosunetuzumab in heavily pretreated FL patients.

CONCLUSION

The effectiveness of this drug is confirmed in our center.